DANIEL SCOTT FITELSON MD
Prescription History 1053545459
Internal Medicine - Critical Care Medicine in Burlington, MA

NPI Status: Active since May 13, 2009

Contact Information

41 MALL RD
LAHEY HOSPITAL AND MEDICAL CENTER
BURLINGTON, MA
ZIP 01805
Phone: (781) 744-8480

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DANIEL SCOTT FITELSON MD, an active Critical Care Medicine specialist practicing in Burlington, MA. Our medical registry currently tracks 33 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 2,005 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 253 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 40.0
Days Supply 1,200
MA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills38.0
Peer Average Days Supply1,136
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,231.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$651.14

State Avg Cost Per Claim

$631.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 73
30-Day Fills 90.0
Days Supply 2,700
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply930
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 204.2% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $40,991.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$561.52

State Avg Cost Per Claim

$611.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 253
30-Day Fills 311.1
Days Supply 7,594
MA State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills63.0
Peer Average Days Supply1,531
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 377.4% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,202.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.37

State Avg Cost Per Claim

$47.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 203
30-Day Fills 275.0
Days Supply 8,250
MA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills50.2
Peer Average Days Supply1,488
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 420.5% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $128,100.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$631.04

State Avg Cost Per Claim

$583.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 26.0
Days Supply 780
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply925
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,921.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$432.58

State Avg Cost Per Claim

$298.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 71.9
Days Supply 2,151
MA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills54.6
Peer Average Days Supply1,598
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,080.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.85

State Avg Cost Per Claim

$50.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 90
30-Day Fills 118.0
Days Supply 2,851
MA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply310
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 210.3% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,213.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.49

State Avg Cost Per Claim

$9.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 82
30-Day Fills 102.0
Days Supply 3,060
MA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills46.0
Peer Average Days Supply1,360
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 127.8% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $40,988.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$499.86

State Avg Cost Per Claim

$496.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 58
30-Day Fills 66.0
Days Supply 1,980
MA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply838
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 176.2% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,924.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$291.80

State Avg Cost Per Claim

$360.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Cefpodoxime Proxetil

Generic Formulation: Cefpodoxime ProxetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 139
MA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.9
Peer Average Days Supply147
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,150.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$76.67

State Avg Cost Per Claim

$60.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of its active metabolite CEFPODOXIME.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 19.5
Days Supply 576
MA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply767
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,656.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$853.54

State Avg Cost Per Claim

$605.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 135
MA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.1
Peer Average Days Supply446
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $150.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.53

State Avg Cost Per Claim

$24.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dupixent Pen

Generic Formulation: DupilumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
MA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply626
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $46,420.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,570.83

State Avg Cost Per Claim

$3,717.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Esbriet

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
MA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.2
Peer Average Days Supply664
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $277,968.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,691.09

State Avg Cost Per Claim

$10,220.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 45
30-Day Fills 59.0
Days Supply 1,744
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills37.5
Peer Average Days Supply1,121
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 87.5% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,352.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$363.40

State Avg Cost Per Claim

$428.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 76.0
Days Supply 2,280
MA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills83.6
Peer Average Days Supply2,498
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $653.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.15

State Avg Cost Per Claim

$18.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 43
30-Day Fills 51.0
Days Supply 1,530
MA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply725
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 115.0% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,822.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$181.92

State Avg Cost Per Claim

$186.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Furosemide

Generic Formulation: FurosemideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 55.0
Days Supply 1,514
MA State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills137.6
Peer Average Days Supply3,850
Conservative Utilization

This provider writes prescriptions for this formulation 49.3% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $273.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.40

State Avg Cost Per Claim

$6.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 43
30-Day Fills 61.0
Days Supply 1,830
MA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,189
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.4% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,057.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$536.22

State Avg Cost Per Claim

$453.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Levalbuterol Tartrate Hfa

Generic Formulation: Levalbuterol TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 18.4
Days Supply 515
MA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply521
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,376.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$91.79

State Avg Cost Per Claim

$70.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levalbuterol is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). It is a quick-relief drug. Levalbuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This drug is not approved for use in children younger than 4 years due to increased risk of side effects (such as unusual fast breathing, worsening asthma). Ask your doctor or pharmacist for details.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 94.0
Days Supply 2,800
MA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills81.6
Peer Average Days Supply2,413
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $837.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.38

State Avg Cost Per Claim

$20.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 37.0
Days Supply 1,110
MA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.6
Peer Average Days Supply528
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 117.6% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $190,631.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,152.19

State Avg Cost Per Claim

$7,159.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 144
30-Day Fills 161.2
Days Supply 2,837
MA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,107
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 227.3% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $799.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.55

State Avg Cost Per Claim

$6.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Qvar Redihaler

Generic Formulation: Beclomethasone DipropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 23.0
Days Supply 690
MA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills23.2
Peer Average Days Supply695
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,032.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$287.28

State Avg Cost Per Claim

$300.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA.

Therapeutic Applications

Beclomethasone is used to prevent and treat seasonal and year-round allergy symptoms (such as stuffy/runny nose, itchy eyes/nose/throat, sneezing). It may be used to treat symptoms (such as stuffy/runny nose) caused by other triggers (such as cigarette smoke, perfumes). It is also used to prevent the return of growths in the nose (nasal polyps) after removal by surgery. Beclomethasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) in the nasal passages.

Sildenafil Citrate

Generic Formulation: Sildenafil CitrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 40.0
Days Supply 1,200
MA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply738
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,134.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$297.26

State Avg Cost Per Claim

$131.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Sildenafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise. This medication is not recommended for use in children. Discuss the risks and benefits of this medication with the doctor.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 53
30-Day Fills 83.0
Days Supply 2,490
MA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills44.8
Peer Average Days Supply1,343
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.6% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,609.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$785.09

State Avg Cost Per Claim

$667.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 51.0
Days Supply 1,530
MA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply1,087
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,204.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,052.37

State Avg Cost Per Claim

$597.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 133
30-Day Fills 169.0
Days Supply 5,070
MA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,424
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 303.0% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67,734.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$509.28

State Avg Cost Per Claim

$539.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Tadalafil

Generic Formulation: TadalafilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
MA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills36.9
Peer Average Days Supply1,100
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,234.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,401.93

State Avg Cost Per Claim

$885.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Tadalafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 201
30-Day Fills 244.0
Days Supply 7,320
MA State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills76.3
Peer Average Days Supply2,272
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 235.0% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $155,989.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$776.07

State Avg Cost Per Claim

$802.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Uptravi

Generic Formulation: SelexipagSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 56
30-Day Fills 56.0
Days Supply 1,634
MA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,187
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.6% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $885,546.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,813.34

State Avg Cost Per Claim

$21,378.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). It is used to help slow down worsening of PAH and to decrease the chance of needing treatment in a hospital. Selexipag works by making it easier for blood to flow through the arteries in your lungs. This effect helps increase your ability to exercise.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 76
30-Day Fills 81.2
Days Supply 1,884
MA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills34.3
Peer Average Days Supply814
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 153.3% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,111.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.26

State Avg Cost Per Claim

$74.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 43
30-Day Fills 69.0
Days Supply 2,070
MA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills30.8
Peer Average Days Supply923
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 104.8% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,900.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$230.24

State Avg Cost Per Claim

$249.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DANIEL SCOTT FITELSON MD provides transparency into local medical care patterns within Burlington, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Critical Care Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.